spECTRUM

1. Scope and goals

The International Consortium for Therapeutic Drug Monitoring (spECTRUM) is a global collaboration comprising 53 scientists—including 49 gastroenterologists, 1 dermatologist, 1 rheumatologist, 1 clinical pharmacist, and 1 pharmacometrics specialist—from 23 countries across five continents. The consortium is dedicated to evaluating the clinical utility of therapeutic drug monitoring (TDM) of biologics in inflammatory bowel disease (IBD), with the overarching aim of advancing personalized medicine and improving patient care.

Scope:

• To define the clinical impact and utility of TDM for biologic therapies in IBD.

Goals:

1. Develop large-scale clinical databases and conduct both retrospective and prospective studies to address key knowledge gaps.
2. Initiate randomized controlled clinical trials, contingent on funding availability.
3. Conduct surveys of patients and healthcare providers to assess the adoption of TDM and identify barriers to its implementation in clinical practice.
4. Translate insights from TDM in IBD to optimize biologic therapy in other immune-mediated inflammatory disorders, including rheumatoid arthritis and psoriasis.
5. Incorporate emerging innovations, such as point-of-care devices and pharmacokinetic modeling, to enhance the practical application of TDM in clinical care.

2. Members
The consortium consists of 53 members representing 23 countries across five continents, encompassing a multidisciplinary team of specialists focused on advancing TDM in IBD and related conditions.

1. Konstantinos Papamichail (Co-founder) (USA)
2. Laurent Peyrin-Biroulet (Co-founder) (FRA)
3. Adam Cheifetz (Co-founder) (USA)
4. Andres Yarur (USA)
5. Maria Abreu (USA)
6. Byron Vaughn (USA)
7. Marla Dubinsky (USA)
8. Corey Siegel (USA)
9. Peter Irving (UK)
10. Mark Samaan (UK)
11. Nurulamin Noor (UK)
12. Tim Raine (UK)
13. Tariq Ahmad (UK)
14. Nicholas Kennedy (UK)
15. Naila Arebi (UK)
16. Nik Kamperidis (UK)
17. Sailish (Sash) Honap (UK)
18. Philip Hendy (UK)
19. Niels Vande Casteele (USA)
20. Xavier Roblin (FRA)
21. Paul Stephane (FRA)
22. Jonas Halfvarson (SWE)
23. Silvio Danese (ITA)
24. Giulia Roda (USA)
25. Richard Gearry (NZL)
26. Taku Kobayashi (JPN)
27. Natalia Queiroz (BRA)
28. Paulo Kotze (BRA)
29. Iris Dotan (ISR)
30. Bella Ungar (ISR)
31. David Drobne (SLO)
32. Severine Vermeire (BEL)
33. Marc Ferrante (BEL)
34. Erwin Dreesen (BEL)
35. Jo Lambert (BEL)
36. Waqqas Afif (CAN)
37. Talat Bessissow (CAN)
38. Robert Battat (CAN)
39. Gertjan Wolbink (NL)
40. Krisztina Gecse (NL)
41. Miles Sparrow (AUS)
42. Mark Ward (AUS)
43. Susan Connor (AUS)
44. Sara El Ouali (UAE)
45. Kostas Karmiris (GRE)
46. Byong Duk Ye (KOR)
47. Joanna Torres (POR)
48. Javier Gisbert (ESP)
49. Maria Chaparro (ESP)
50. Walter Reinisch (AUT)
51. Murat Toruner (TUR)
52. Kristin Kaasen Jorgensen (NOR)
53. Sophie Restellini (SWI)

3. Publications

• Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol 2022 Feb;7(2):171-185.
• Papamichael K, Centritto A, Guillo L, Hier J, Sherman Z, Cheifetz AS; International Consortium of Therapeutic Drug Monitoring (Spectrum). Higher Adalimumab Concentration is Associated with Complete Fistula Healing in Patients with Perianal Fistulizing Crohn's Disease. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2134-2136.
• Honap S, Caron B, Ollech JE, Fischman M, Papamichael K, De Jong D, Gecse KB, Centritto A, Samaan MA, Irving PM, Sparrow MP, Karmiris K, Chateau T, Dotan I, Laurent Peyrin-Biroulet, on behalf of the International Consortium for Therapeutic Drug Monitoring (spECTRUM). Anti-tumour necrosis factor drug concentration is not associated with disease outcomes in pouchitis: a retrospective, international, multi-centre, cross-sectional study. Dig Dis Sci 2025 Apr;70(4):1320-1327.

4. Photos